Cue Biopharma reported a significant increase in net loss for the third quarter of 2026, primarily driven by non-cash stock-based compensation and rising clinical trial costs. The company ended the period with $57.9 million in cash and cash equivalents, supported by a restructured licensing agreement with ImmunoScape that adds $5.5 million in staggered payments through 2027.

Key Highlights

  • Net loss per share expanded to $(4.74) for the quarter, compared to $(2.22) in the prior-year period, largely due to $46.8 million in total operating expenses.
  • Phase 2 CSU findings for CUE-221 demonstrated that 78% of high baseline IgE patients achieved complete hive resolution (HSS7=0) at the 4 mg/kg dose level.
  • Research and development expenses surged to $17.0 million from $4.8 million year-over-year, reflecting the initiation of the CUE-401 first-in-human Phase 1 trial.